title: Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
abstract: The extent of nigrostriatal denervation is presumed to play a role in the genesis of levodopa-induced dyskinesia. Yet some parkinsonian patients who have been treated over a long period do not develop dyskinesia, raising the possibility that the pattern of denervation is as important as the extent of lesioning as a risk factor. Here we study the extent and pattern of nigrostriatal denervation in a homogeneous population of parkinsonian macaque monkeys chronically treated with levodopa. Based on the characteristics of the lesioning, non-dyskinetic animals could not be differentiated from those with dyskinesia. Indeed, the number of tyrosine-hydroxylase (TH)-immunopositive neurons in the substantia nigra pars compacta, striatal dopamine transporter (DAT) binding and TH immunostaining, as well as the overall TH striatal content measured by Western blotting were identical. Moreover, the patterns of lesioning assessed by a detailed analysis of the TH- and DAT-immunopositive striatal fibers were comparable in all functional quadrants and at all rostro-caudal levels considered. These data indicate that neither the extent nor the pattern of nigrostriatal lesioning are sufficient to explain the occurrence of levodopa-induced dyskinesia.
authors: Laboratoire de Physiologie et Physiopathologie de la Signalization Cellulaire, CNRS UMR 5543, Universite victor Segalen-Bordeaux, 33076 Bordeaux Cedex, France.
authors: Céline
authors: C
authors: Guigoni
authors: Sandra
authors: S
authors: Dovero
authors: Incarnation
authors: I
authors: Aubert
authors: Qin
authors: Q
authors: Li
authors: Bernard H
authors: BH
authors: Bioulac
authors: Bertrand
authors: B
authors: Bloch
authors: Eugenia V
authors: EV
authors: Gurevich
authors: Christian E
authors: CE
authors: Gross
authors: Erwan
authors: E
authors: Bezard
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects; D002452:Cell Count; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D003342:Corpus Striatum / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D050483:Dopamine Plasma Membrane Transport Proteins; D004409:Dyskinesia, Drug-Induced / Q000473:pathology* / Q000503:physiopathology; D005260:Female; D007150:Immunohistochemistry; D007980:Levodopa / Q000009:adverse effects*; D008252:Macaca fascicularis; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000378:metabolism; D009410:Nerve Degeneration / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009434:Neural Pathways / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D007980:Levodopa; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine